Veranova has appointed Dr. Scott Zugel as Global Vice President of Analytical Research Development Operations.

Zugel brings 25 years of experience in the chemical and pharmaceutical industries, with extensive expertise in the analytical development of both small and large molecules. He is well-versed in the development and validation of assay, purity, and dissolution methods for combination therapies containing multiple active pharmaceutical ingredient (API) formulations, with proven success in obtaining new drug application (NDA) approvals for a wide variety of drug indications.

Most recently, Zugel served as the Head of Analytical Development (USA) at Takeda Pharmaceuticals where he led analytical activities across multiple sites and successfully merged legacy biologics and synthetic molecule analytical development teams into a cohesive department. He is also credited with centralizing Takeda’s GMP analytical testing labs and establishing the first internal metrology team. Before joining Takeda, Zugel spent seven years with Pfizer Global R&D, where he held several roles, ultimately becoming a Laboratory Leader.

Zugel holds a Ph.D. in Analytical Chemistry from Purdue University and a B.S. in Chemistry from Valparaiso University. His contributions to the field are well-recognized, with multiple publications, numerous presentations, and long-standing membership in the Analytical Leadership Group in the IQ Consortium. He has also been honored by organizations such as Millennium and Pfizer and has completed fellowships with the Purdue Research Foundation Fellowship and the Brown-Wetherill Fellowship.

“We are delighted to welcome Dr. Scott Zugel as our Global Vice President of Analytical Development Operations,” said Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer at Veranova. “His wealth of experience and track record of excellence make him a valuable asset to our team as we continue to advance our global R&D strategy and drive pharmaceutical success for our partners.”